Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial.

The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients

Moderate weight loss improves metabolic and cardiovascular risk factors and prevents the progression to Type 2 diabetes. Furthermore, a healthy lifestyle is associated with lower cardiovascular mortality, whereas sustained weight loss and increased fitness are both associated with reduced cardiovascular mortality. Currently available antiobesity drugs have been shown to deliver moderate weight ...

Disconnection of the right pulmonary artery with bilateral ductus arteriosus.

1. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramineassociated adverse effects: a practical quide for its safe use. Obes Rev. 2008;9:378-87. 2. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, van Gaal L, Maggioni A, et al; on the behalf of the SCOUT Investigators. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an análisis from the SCOUT trial. Eur Hear...

The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period

BACKGROUND Obesity, type 2 diabetes mellitus (T2D) and unhealthy blood lipid profile are strongly associated with the risk of developing cardiovascular disease (CVD). We examined whether blood lipid changes with short term administration of the weight lowering drug, sibutramine and lifestyle modification in obese and overweight high-risk patients was associated with T2D status at screening. M...

Author's response to reviews Title: The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period Authors:

Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial

BACKGROUND AND AIMS Elevated levels of serum uric acid are associated with an increased risk of cardiovascular morbidity and mortality. The response of uric acid to weight loss therapy (lifestyle plus sibutramine) in an overweight and obese cardiovascular high risk population was studied. METHODS AND RESULTS Data from a four week single-blind lead-in period of the Sibutramine Cardiovascular O...